Edgewise Therapeutics, Inc. (EWTX)

Market Cap	2.90B
Revenue (ttm)	n/a
Net Income (ttm)	-157.24M
Shares Out	105.87M
EPS (ttm)	-1.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,436,335
Open	26.55
Previous Close	26.60
Day's Range	25.92 - 27.51
52-Week Range	10.60 - 30.48
Beta	0.27
Analysts	Buy
Price Target	34.13 (+24.61%)
Earnings Date	Mar 2, 2026

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: EWTX
• Website: https://edgewisetx.com

Analyst Summary

According to 8 analysts, the average rating for EWTX stock is "Buy." The 12-month stock price target is $34.13, which is an increase of 24.61% from the latest price.

Price Target

$34.13

(24.61% upside)

Analyst Consensus: Buy